Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program

Loading news article.

Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program | WAPE

Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program

Article summary

Related companies

Comments —